Replies to post #218067 on Biotech Values

[DewDiligence]

PTLA is appealing the CHMP's rejection of Betrixaban:

https://finance.yahoo.com/news/portola-pharmaceuticals-receives-plans-appeal-130641159.html

PTLA could prevail with the EMA/CHMP, but I doubt it insofar as they were lucky to get FDA approval for Betrixaban based on a single phase-3 with meh results.